GeoVax Labs (GOVX) Non Operating Income (2010 - 2025)
GeoVax Labs (GOVX) posted quarterly Non Operating Income of $23333.0 for Q4 2025, down 71.46% year-over-year from $81748.0 in Q4 2024, and down 57.03% quarter-over-quarter from $54301.0 in Q3 2025.
GeoVax Labs (GOVX) Non Operating Income (2010 - 2025) Analysis & Trends
GeoVax Labs (GOVX) has reported Non Operating Income for 16 consecutive years, with $23333.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Non Operating Income fell 71.46% year-over-year to $23333.0; the TTM figure through Dec 2025 stood at $208505.0 (down 5.39% YoY), while the FY2025 annual figure was $174276.0, up 14.67% from the prior year.
- Non Operating Income fell to $23333.0 in Q4 2025 per GOVX's latest filing, from $54301.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $251201.0 in Q2 2023 and bottomed at -$1821.0 in Q2 2024.
- Historically, Non Operating Income has averaged $57189.2 across 5 years, with a median of $23333.0 in 2025.
- Annual changes were most pronounced in 2023 — Non Operating Income jumped 31737.9% — and 2024, when it sank 100.72%.
- GeoVax Labs' Non Operating Income stood at $738.0 in 2021, then soared by 400.27% to $3692.0 in 2022, then soared by 2644.91% to $101342.0 in 2023, then decreased by 19.33% to $81748.0 in 2024, then tumbled by 71.46% to $23333.0 in 2025.
- Business Quant data shows GOVX's Non Operating Income at $23333.0 in Q4 2025, $54301.0 in Q3 2025, and $49123.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | GeoVax Labs | 2.88 Mn | -260,493.75 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 23,333.00 |
| Sep 30, 2025 | 54,301.00 |
| Jun 30, 2025 | 49,123.00 |
| Dec 31, 2024 | 81,748.00 |
| Sep 30, 2024 | 39,108.00 |
| Jun 30, 2024 | -1,821.00 |
| Dec 31, 2023 | 101,342.00 |
| Sep 30, 2023 | 190,936.00 |
| Jun 30, 2023 | 251,201.00 |
| Dec 31, 2022 | 3,692.00 |
| Sep 30, 2022 | 2,431.00 |
| Jun 30, 2022 | 789.00 |
| Mar 31, 2022 | 527.00 |
| Dec 31, 2021 | 738.00 |
| Sep 30, 2021 | 877.00 |
| Jun 30, 2021 | 172,593.00 |
| Mar 31, 2021 | 1,298.00 |
| Dec 31, 2020 | 567.00 |
| Sep 30, 2020 | -134,337.00 |
| Jun 30, 2020 | -7,093.00 |